✦ LIBER ✦

5.25 Safety and Tolerability of Oral Fludarabine, with or without Oral Cyclophosphamide and Intravenous Rituximab Therapy, in Previously Untreated Patients with Chronic Lymphocytic Leukaemia Aged 65 Years or Older: Second Interim Analysis from the Australasian Leukaemia and Lymphoma Group and CLL Australian Research Consortium CLL5 Study

✍ Scribed by Stephen P. Mulligan; Devinder Gill; Paul Turner; William Renwick; Rosemary Harrup; Maya Latimer; Leanne Berkahn; David Simpson; Melanie Sulda; Giles Best; Bryone Kuss; Gavin Cull

Book ID: 119218970
Publisher: Elsevier
Year: 2011
Tongue: English
Weight: 181 KB
Volume: 11
Category: Article
ISSN: 2152-2650
DOI: 10.1016/j.clml.2011.09.179

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

5.44 Consolidation Therapy with Subcutan

5.44 Consolidation Therapy with Subcutaneous Alemtuzumab after Induction Treatment with Oral Fludarabine and Cyclophosphamide in Previously Untreated Patients Aged 65-70 years with Advanced Stage CLL: Final Results of a Phase II Study from the French Cooperative Group on Chronic Lymphocytic Leukemia and Waldenstrom Macroglobulinemia (FCG-CLL/WM)

✍ Alain Delmer; Olivier Tournilhac; Stéphane Leprêtre; Bruno Cazin; Pierre Feugier 📂 Article 📅 2011 🏛 Elsevier 🌐 English ⚖ 113 KB